191 related articles for article (PubMed ID: 19786739)
21. Changing patterns of anemia management in US hemodialysis patients.
Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
[TBL] [Abstract][Full Text] [Related]
22. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
24. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
25. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
26. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
Ludwig H; Aapro M; Bokemeyer C; Macdonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
Eur J Cancer; 2009 Jun; 45(9):1603-15. PubMed ID: 19278851
[TBL] [Abstract][Full Text] [Related]
27. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
28. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
29. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
30. [Hemoglobin variability in patients with chronic renal insuffiency].
Deray G
Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
[TBL] [Abstract][Full Text] [Related]
31. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
32. Stabilizing hemoglobin levels: what's new in IV iron and anemia management?
Fishbane S; Larson K; VanBuskirk S
Nephrol Nurs J; 2008; 35(5):493-502. PubMed ID: 18856080
[TBL] [Abstract][Full Text] [Related]
33. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
34. Hemoglobin level variability in renal transplant patients treated with erythropoiesis stimulating agents.
Fernández Fresnedo G; de Francisco AL; Ruiz JC; Gómez Alamillo C; Arias M
Transplant Proc; 2008 Nov; 40(9):2919-21. PubMed ID: 19010147
[TBL] [Abstract][Full Text] [Related]
35. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
36. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
[TBL] [Abstract][Full Text] [Related]
37. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery.
Kulier A; Levin J; Moser R; Rumpold-Seitlinger G; Tudor IC; Snyder-Ramos SA; Moehnle P; Mangano DT; ;
Circulation; 2007 Jul; 116(5):471-9. PubMed ID: 17620512
[TBL] [Abstract][Full Text] [Related]
38. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices.
Pisoni RL; Bragg-Gresham JL; Fuller DS; Morgenstern H; Canaud B; Locatelli F; Li Y; Gillespie B; Wolfe RA; Port FK; Robinson BM
Am J Kidney Dis; 2011 Feb; 57(2):266-75. PubMed ID: 21251541
[TBL] [Abstract][Full Text] [Related]
39. Hemoglobin variability and hyporesponsiveness: much ado about something or nothing?
Yee J; Zasuwa G; Frinak S; Besarab A
Adv Chronic Kidney Dis; 2009 Mar; 16(2):83-93. PubMed ID: 19233067
[TBL] [Abstract][Full Text] [Related]
40. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
Locatelli F; Covic A; Macdougall IC; Wiecek A;
J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
